In December 2013 Eli Lilly and Company (NYSE:LLY) acquired all development rights for Arteaus Therapeutics’ calcitonin gene-related peptide (CGRP) antibody upon the completion of a Phase 2a clinical trial for the prevention of frequent, recurrent migraine headaches.
Atlas wraps Arteaus story with $260M royalty sale as Emgality sales inches upward
Arteaus’ Final Chapter: Monetization Of The Emgality Royalties
The Arteaus Therapeutics Story: R&D Externalization with Eli Lilly
Arteaus: Meeting of the Minds
Lilly Buys Back Rights to Experimental Migraine Drug
Location: United States, Massachusetts, Cambridge
Member count: 51-200
Total raised: $18M
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | Atlas Vent... | atlasventu... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 19.10.2011 | - | $18M | - | finsmes.co... |
Mentions in press and media 4
| Date | Title | Description | Source |
| 08.07.2015 | Cambridge-based Compass Therapeutics raising $120M for antib... | On its LinkedIn page, Compass Therapeutics bills itself as an antibody discovery and development com... | medcitynew... |
| 19.10.2011 | Arteaus Therapeutics Raises $18M | Biotechnology development company focused on creating new therapies for migraine prevention, has r... | vcnewsdail... |
| 19.10.2011 | Arteaus Therapeutics Raises $18M in Funding | Arteaus Therapeutics, LLC, a Cambridge, Massachusetts-based biotechnology development company focuse... | finsmes.co... |
| - | Cambridge-based Compass Therapeutics raising $120M for antib... | Looks as though a new Cambridge startup in the space of antibody drug development is revving up to m... | medcitynew... |